NCT02596230

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 7,797 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RE-COVERY is a large, multi-national, multi-center observational study based on new data collection. The study will enroll and characterize patients within 30 days of being diagnosed with an acute DVT and/or PE. The study has two main objectives. Objective 1 will characterize the DVT / PE patient population. All patients with a DVT and/or PE will be enrolled for cross-sectional characterization of the VTE patient population. Objective 2 will compare the safety and effectiveness of dabigatran etexilate regimens for treatment of VTE in comparison to VKA regimens. Patients treated with dabigatran etexilate or VKA will be followed up for the occurrence of outcome events for up to one year.

Conditions

• Venous Thromboembolism

Timeline

• Start date: 2015-11-05
• Primary completion: 2019-03-31
• Completion: 2019-03-31
• First posted: 2015-11-04
• Last updated: 2020-04-29
• Results posted: 2020-04-29

Locations

222 sites across 37 countries: United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Egypt, Germany, Greece, Hungary, Italy, Latvia, Lebanon, Malaysia, Mexico, Netherlands, New Zealand, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Serbia, Slovakia, Slovenia, South Korea, Thailand, Turkey (Türkiye), United Arab Emirates, United Kingdom, Vietnam